Table 1 Demographics and clinical characteristics of study population (N = 1394)
| Â | Total IBD | CD | UC |
|---|---|---|---|
Number (%) | 1394 (100) | 834 (59.8) | 560 (40.2) |
Median diagnosis age (years, range) | 33 (23–46) | 32 (22–46) | 35 (24–46) |
Sex (females, %) | 635 (45.6) | 389 (46.6) | 246 (43.9) |
Median IBD durationa (years, range) | 3 (1–9) | 3 (1–8.25) | 3 (1–10) |
Active smokers (%) | 442 (31.7) | 330 (39.5) | 112 (20) |
Ex-smokers (%) | 366 (26.2) | 189 (22.7) | 177 (31.6) |
Never smoked (%) | 586 (42.1) | 315 (37.8) | 271 (48.4) |
Median BMI (range) | 24.5 (21.5–27.8) | 24.3 (21.5–27.9) | 24.7 (21.6–27.7) |
Montreal classification for UC | |||
 Proctitis (E1, %) |  |  | 63 (11.25) |
 Left sided colitis (E2, %) |  |  | 237 (42.5) |
 Extensive colitis (E3, %) |  |  | 259 (46.25) |
Montreal classification for CD | |||
IÂ nflammatory (B1, %) | Â | 515 (61.8) | Â |
 Stricturing (B2, %) |  | 190 (22.8) |  |
 Penetrating (B3, %) |  | 129 (15.4) |  |
 Perianal (p, %) |  | 165 (19.8) |  |
 Ileum (L1, N, %) |  | 376 (45.0) |  |
 Colon (L2, N, %) |  | 79 (9.5) |  |
 Ileocolonic (L3, N, %) |  | 380 (45.5) |  |
 Upper GI (L4, N, %) |  | 114 (13.7) |  |
 EIMs (%) | 469 (33.6) | 325 (38.9) | 144 (25.7) |
 Anti-TNFs (N, %) | 692 (49.6) | 495 (59.4) | 197 (35.2) |
 Immunomodulators (N, %) | 529 (37.9) | 380 (45.6) | 149 (26.6) |
 Other biologics (N, %) | 230 (16.5) | 131 (15.7) | 99 (17.7) |
 IBD-related surgery (N, %) | 176 (12.6) | 156 (18.7) | 20 (3.6) |